预防和控制心脑血管疾病五个金标准（五A标准）
庞会心3 刘大力4 任安静5 余联芳2 贾大成1 郭玉春5 牛志军5

1北京急救中心，北京，100000；

2武警总医院保健科，北京，100101；

3全国卫生产业企业管理协会，北京，100101；

4北京汉福科技管理有限公司，北京，100101；

5全国卫生产业企业管理协会养生康复产业分会，北京，100101；

摘要：心脑血管病是全球致死和致残率最高的疾病。我国目前拥有患者3.3亿之多。针对当前医疗体系简单干预模式的局限性，本文整合现代循证医学与传统中医智慧，提出了预防和控制心脑血管疾病的五个金标准，即“五A标准”。1A：调节血脂，以降低LDL-C为核心基石；2A：控制斑块，稳定、逆转斑块是预防心梗脑梗的关键目标；3A：稀释血稠，针对高黏血症这一独立危险因素，中医药的多靶点干预策略优势明显；4A：软化血管，以延缓与控制动脉硬化进展为主；5A：活血化瘀，体现中医学“治未病”思想，贯穿心梗脑梗预防全周期。该“五A标准”的提出旨在整合中西医优势，对心脑血管疾病复杂的发病因素进行综合控制，为降低心梗脑梗的发生率并实现健康老龄化提供科学参考。

关键词：心脑血管疾病；五A标准；预防；调节血脂；控制斑块；高黏血症；动脉硬化；血管衰老；活血化瘀

参考文献

[1]Banach,Maciej et al.“Primary and secondary cardiovascular prevention:Recent advances.”Kardiologia polska vol.82,12(2024):1200-1210.

[2]Ordunez,Pedro et al.“HEARTS in the Americas: innovations for improving hypertension and cardiovascular disease risk management in primary care.”Revista panamericana de salud publica=Pan American journal of public health vol.46 e96.16 Jul.2022

[3]国家心血管病中心, 中国心血管健康与疾病报告编写组.中国心血管健康与疾病报告2023概要[J].中国循环杂志,2024,39(07):625-660.

[4]崔连群,孙海慧,崔玉奇等.医万个为什么全民大健康医学科普丛书：心血管密码——心血管健康科普问答[M].济南:山东大学出版社,2025.01.

[5]中华医学会神经病学分会,中华医学会神经病学分会脑血管病学组.中国缺血性卒中和短暂性脑缺血发作二级预防指南2022[J].中华神经科杂志,2022,55(10):1071-1110.

[6]中华医学会心血管病学分会,中国康复医学会心脏预防与康复专业委员会,中国老年学和老年医学会心脏专业委员会,等.中国心血管病一级预防指南基层版[J].中华心血管病杂志,2023,51(04):343-363.

[7]《中国血脂管理指南》修订联合专家委员会.中国血脂管理指南.2023.

[8]Maciej B, et al.Red yeast rice for dyslipidaemias and cardiovascular risk reduction: A Position Paper of the International Lipid Expert Panel[J].Pharmacological research,2022,183106370-106370.

[9]刘春丽,蔡辉.动脉粥样硬化斑块不稳定性因素的研究进展[J].实用医学杂志,2012,28(15):2636-2638.

[10]马乾凤,宁传永,赵梦,等.颈动脉粥样硬化斑块稳定性影响因素分析[J].宁夏医学杂志,2023,45(08):708-710.

[11]Musialek, Piotr et al. “ESC consensus statement on stroke risk management in carotid atherosclerotic disease: 10 key points.” European heart journal vol. 46,41 (2025): 4150-4153.

[12]邢运虹,李洋,王文政,等.不稳定冠状动脉粥样斑块病理特征及分类[J].法医学杂志,2024,40(01):59-63.

[13]Mury, Pauline et al. “Oxidative Stress and Inflammation, Key Targets of Atherosclerotic Plaque Progression and Vulnerability: Potential Impact of Physical Activity.”Sports medicine (Auckland, N.Z.)vol.48,12(2018):2725-2741.

[14]郝炎,陈明.动脉粥样硬化斑块不稳定性机制的研究进展[J].实用医学杂志,2011,27(04):708-710.

[15]廖玉华,程翔,黄恺,等.ASCVD患者逆转斑块他汀治疗专家共识[J].临床心血管病杂志,2015,31(01):1-5.

[16]杨进刚,杨跃进.以逆转斑块为目标的时代已经来临?——《动脉粥样硬化性心血管疾病患者逆转斑块他汀治疗专家共识》解读[J].中国循环杂志, 2015, 30(0Z2):77-79.

[17]吴丽敏,贺晓鸣,陈卫建,等.中西医结合治法对“脾虚血瘀”型患者颈动脉粥样硬化斑块的逆转作用研究[J].时珍国医国药,2022,33(05):1175-1177.

[18]Ye,Weile et al.“Anti-atherosclerotic effects and molecular targets of ginkgolide B from Ginkgo biloba.”Acta pharmaceutica Sinica.B vol.14,1(2024):1-19.

[19]Su, Wenquan et al. “Comparative efficacy of Chinese patent medicines in patients with carotid atherosclerotic plaque: a Bayesian network meta-analysis.” Chinese medicine vol. 18,1 152. 20 Nov. 2023.

[20]Qiao, Yun et al. “Panax notoginseng saponins inhibits atherosclerotic plaque angiogenesis by down-regulating vascular endothelial growth factor and nicotinamide adenine dinucleotide phosphate oxidase subunit 4 expression.” Chinese journal of integrative medicine vol. 21,4 (2015): 259-65.

[21]程志清.香遇杏林——中医芳香应用指引[M]. 北京:中国中医药出版社,2022.09.

[22]彭振荣.益心舒胶囊联合拜阿司匹灵治疗冠心病高黏稠血症随机平行对照研究[J].实用中医内科杂志,2013,27(04):33-34.

[23]Peters, Sanne Ae et al. “Plasma and blood viscosity in the prediction of cardiovascular disease and mortality in the Scottish Heart Health Extended Cohort Study.” European journal of preventive cardiology vol. 24,2 (2017): 161-167.

[24]Mbah, Jovita I et al. “Seasonal Variations in Estimated Whole Blood Viscosity Associated with HbA1c: Evidence from Retrospective Pathology Review for Diabetes Management.” International journal of molecular sciences vol. 27,1 368. 29 Dec. 2025

[25]Crawford, Vivienne L S et al. “Seasonal changes in platelets, fibrinogen and factor VII in elderly people.” Age and ageing vol. 32,6 (2003): 661-5.

[26]Phillips, P A et al. “Reduced thirst after water deprivation in healthy elderly men.” The New England journal of medicine vol. 311,12 (1984): 753-9.

[27]Tian, Ying et al. “Down regulation of renal vasopressin V2 receptor and aquaporin-2 expression parallels age-associated defects in urine concentration.” American journal of physiology. Renal physiology vol. 287,4 (2004): F797-805.

[28]Kenny, Glen P et al. “Heat stress in older individuals and patients with common chronic diseases.” CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne vol. 182,10 (2010): 1053-60.

[29]Ryti, Niilo R I et al. “Cold Weather and Cardiac Arrest in 4 Seasons: Helsinki, Finland, 1997‒2018.” American journal of public health vol. 112,1 (2022): 107-115.

[30]Wilmshurst, P. “Temperature and cardiovascular mortality.” BMJ (Clinical research ed.) vol. 309,6961 (1994): 1029-30.

[31]王瑞来.益心舒胶囊联合西药治疗冠心病稳定型心绞痛疗效及对红细胞分布宽度、总胆红素、平均血小板体积的影响分析[J].世界复合医学,2022,8(07):120-123.

[32]Xu, Min et al. “Traditional medicine in China for ischemic stroke: bioactive components, pharmacology, and mechanisms.” Journal of integrative neuroscience vol. 21,1 (2022): 26.

[33]程荷珍,程焱华.三七对高黏血症患者血液流变学的影响[J].湖北中医杂志,2013,35(02):23-24.

[34]王阶,李军,董艳,等.泛血管疾病的中医内涵及防治策略[J].中国实验方剂学杂志,2025,31(07):1-14.

[35]Li, Dan et al. “Mechanism and Potential Target of Blood-Activating Chinese Botanical Drugs Combined With Anti-Platelet Drugs: Prevention and Treatment of Atherosclerotic Cardiovascular Diseases.” Frontiers in pharmacology vol. 13 811422. 3 Jun. 2022.

[36]闫泉香,冯利,徐峰,等.纳豆激酶的溶栓作用及其机制研究[J].食品工业科技,2021,42(24):340-346.

[37]刘玉猛,刘英华.纳豆激酶在血管性疾病防治中的研究进展[J].中国食物与营养,2020,26(12):41-44.

[38]Chen, Hongjie et al. “Effective management of atherosclerosis progress and hyperlipidemia with nattokinase: A clinical study with 1,062 participants.” Frontiers in cardiovascular medicine vol. 9 964977. 22 Aug. 2022

[39]Gallelli, Giuseppe et al. “Data Recorded in Real Life Support the Safety of Nattokinase in Patients with Vascular Diseases.” Nutrients vol. 13,6 2031. 13 Jun. 2021

[40]Granito, Mariana et al. “Nattokinase as an adjuvant therapeutic strategy for non-communicable diseases: a review of fibrinolytic, antithrombotic, anti-inflammatory, and antioxidant effects.” Expert review of cardiovascular therapy vol. 22,10 (2024): 565-574.

[41]王青,刘艳飞,徐仕晗,等.血管衰老与老年泛血管疾病的关系及其中西医结合防治策略[J].世界中医药,2024,19(23):3702-3708.

[42]胡渊龙.基于因瘀致衰理论的丹参川芎药对抗血管衰老延缓动脉粥样硬化进展的隐性知识发现与分子机制研究[D].山东中医药大学,2025.

[43]崔京,李逸雯,刘玥,等.因瘀致衰与血管衰老[J].中国中西医结合杂志,2022,42(04):487-491.

[44]刘艳飞,程冰丽,刘玥,等.活血化瘀方药延缓衰老的研究进展[J].医学研究杂志,2018,47(05):188-191.

[45]Nijat, Dilaram et al. “An Up-to-Date Review of Traditional Chinese Medicine in the Treatment of Atherosclerosis: Components, Mechanisms, and Therapeutic Potentials.” Phytotherapy research : PTR vol. 39,8 (2025): 3709-3735.

[46]Li, Dan et al. “Mechanism and Potential Target of Blood-Activating Chinese Botanical Drugs Combined With Anti-Platelet Drugs: Prevention and Treatment of Atherosclerotic Cardiovascular Diseases.” Frontiers in pharmacology vol. 13 811422. 3 Jun. 2022

[47]黄明艳,陈光,高嘉良,等.基于冠心病全程管理的“治未病”理论和实践[J].中国临床保健杂志,2019,22(06):860-864.

[48]邢天野,林贺,尚晓玲,等.血瘀体质与冠心病、妇科疾病的关系研究[J].吉林中医药,2020,40(06):735-737.

[49]孙静,刘静,王鑫,等.活血化瘀类中药治疗动脉粥样硬化的作用机制研究[J].西部中医药,2025,38(03):84-89.

[50]Hua, Zhen et al. “Plant-derived natural products targeting inflammation in treatment of atherosclerosis.” Frontiers in pharmacology vol. 16 1642183. 2 Oct. 2025

[51]Yuan, Rong et al. “Holistic Regulation of Angiogenesis with Chinese Herbal Medicines as a New Option for Coronary Artery Disease.” Evidence-based complementary and alternative medicine : eCAM vol. 2018 3725962. 13 Aug. 2018

[52]吕宏芳,王晶,梁正,等.中药药对治疗动脉粥样硬化机制的研究进展[J].实用心脑肺血管病杂志,2025,33(11):79-84.

[53]王雪梅,李喜香,宋薇,等.三七药对的研究进展[J].中华中医药学刊,2024,42(05):206-210.

[54]王雅莉,胡光,张倩,等.活血化瘀中药丹参药对的研究进展[J].重庆理工大学学报(自然科学),2020,34(03):197-204.